Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights February 23, 2026 Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million Prothena expects the full year 2026 net cash used in operating and investing activities to be $50 to $55 million and expects to end the year with approximately $255 million in cash (midpoint). Financial guidance does not include the potential to earn up to $105 million in aggregate clinical milestone payments from strategic partners in 2026 Roche initiated the Phase 3 PARAISO trial evaluating prasinezumab in early-stage Parkinson’s disease in 4Q 2025; primary completion expected in 2029 Novo Nordisk initiated the Phase 3 CLEOPATTRA trial evaluating coramitug in ATTR amyloidosis with cardiomyopathy in 4Q 2025; primary completion expected in 2029 Bristol Myers Squibb fully enrolled the Phase 2 TargetTau-1 trial evaluating BMS-986446 in early Alzheimer’s disease with primary completion expected in 1H 2027, completed a Phase 1 trial evaluating a subcutaneous formulation of BMS-986446 and obtained Fast Track designation from the U.S. FDA for BMS-986446 for the treatment of Alzheimer’s disease Prothena presented preclinical data on its TDP-43 CYTOPE® program at Neuroscience 2025 (SfN) and at the International Symposium on ALS/MND demonstrating the potential of Prothena’s CYTOPE® technology to target intracellular disease pathways At the Extraordinary General Meeting on November 19, 2025 Prothena obtained shareholder approval to reduce share capital to create distributable reserves to support a share redemption program to be conducted in 2026 if deemed appropriate Potential to earn up to $105 million in aggregate clinical milestone payments by end of 2026 related to the advancement of both coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb
‘Trust me’: Jamie Dimon to defend JP Morgan’s $2bn-a-week bill February 23, 2026 Jamie Dimon is set to defend JP Morgan’s $2bn-a-week cost bill today as analysts and shareholders gather for the banking giant’s annual investor day. The bank chief – generally considered to be the world’s most influential banker – unveiled higher-than-expected plans for 2026 spend at the beginning of the year. JP Morgan told markets spending [...]
ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM February 23, 2026 Final data from LATITUDE study show switch to long-acting injectable treatment reduced the risk of virological failure by nearly half for study participants through 48 weeks, compared to those continuing on daily oral therapy
Lady Mayor: London must deepen ties with America’s emerging powerhouses February 23, 2026 The US is more than just two coasts. Miami, Dallas and Texas are booking and London is perfectly placed to feel the benefits, says Susan Langley A huge part of the impact of the mayoralty is the 100 days spent overseas, championing the sector and deepening relationships in key markets. When people talk about UK-US [...]
Lattice Launches Joint Cyber Resilience Reference Kit with EXOR International and TrustiPhi to Simplify Secure Device Development February 23, 2026 Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced a Cyber Resilience Reference Kit designed to help industrial and edge device manufacturers accelerate secure system design, developed in collaboration with EXOR International and TrustiPhi. Built on the Lattice MachXO3D™ secure control FPGA, EXOR International’s industrial edge platform, and TrustiPhi’s integrated security orchestration platform, [...]
Graphene Launches Authorised Investment Platform for Alpha Investment Office February 23, 2026 Platform delivers regulated infrastructure, custody connectivity and end-to-end investment operations to support Alpha’s growth strategy
UK tech faces hiring crunch despite AI visa push February 23, 2026 Applications from overseas tech workers wanting to move to the UK have dropped significantly, adding to concerns over talent shortages in one of the economy’s faster growing sectors. New data by accountancy firm RSM UK found the number of international workers applying for a UK visa to work in tech dropped 11 per cent from [...]
How to solve the energy crisis? Give power back to the markets February 23, 2026 Solving the energy crisis needs the dynamism of the private sector, not more government subsidies and central planning, writes Emma Revell.
‘Drastic’ Dave to serve up new vision for Guinness maker Diageo February 22, 2026 It’s been a rocky 12 months for drinks titan Diageo and Sir Dave Lewis will be looking to cure the firm’s long-running hangover when he serves up his future vision next week. Diageo’s stock has tumbled over 15 per cent in the last 12 months with a notable drop in November after operating profit growth [...]
Davey challenges Starmer on Trump tariffs February 21, 2026 The UK Government should sue US President Donald Trump for 100 billion dollars for the damage caused to the UK by trade tariffs, Liberal Democrats leader Sir Ed Davey has insisted. The Lib Dem branded Mr Trump the “most dangerous, damaging US president of modern times” as he welcomed a “brilliant” decision by the US [...]